Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Debiopharm Group
Headquarters: Lausanne, Switzerland
Website: http://www.debiopharm.com
Year Founded: 1979
Status: Private
BioCentury | Feb 20, 2025
Management Tracks
Bourla becomes chair of PhRMA
Plus: Steve Worland named CEO of Atomwise and updates from Ona, Cidara and Biosion
BioCentury | Sep 17, 2024
Deals
Pair of radiopharma deals sees Sanofi dive into 212Pb as ITM gets another 177Lu program
Deals Report: A cardiometabolic deal for Novo Nordisk and updates from BMS-Immatics, Takeda-Innate, Moderna-Carisma and more
BioCentury | Sep 27, 2023
Deals
Insilico’s evolving AI deals: from ‘death by pilot’ to $80M up front
The AI company’s Exelixis partnership highlights its strategic pivots in a shifting landscape
BioCentury | Mar 3, 2023
Finance
March 2 Quick Takes: MorphoSys laying off staff, ending preclinical work
Plus: Flamingo teaming up with Dynacure and updates from Debiopharm, Aldeyra, Checkpoint and more
BioCentury | Jul 8, 2022
Management Tracks
BI’s Fine becomes president of R&D at EvolveImmune
Plus Sallah joins Genespire as CMO, and updates from Kinaset, Andera, Ariceum and more
BioCentury | Apr 1, 2022
Product Development
Merck KGaA is avoiding big pipeline bets as it moves on from bintrafusp alfa
High risk-high reward replaced with well-defined activity in focused indications
BioCentury | Mar 1, 2021
Deals
With Phase III started in head and neck cancer, Debiopharm partners lead program with Germany’s Merck
Debiopharm will bank €188 million ($226.6 million) for pipeline development now that the biotech has partnered lead program xevinapant with Merck KGaA, adding the German biopharma’s
BioCentury | May 26, 2020
Distillery Therapeutics
Blocking inhibitor of apoptosis proteins in liver cells to treat malaria
BioCentury | Jun 7, 2019
Targets & Mechanisms
Following PARP, ATR axis next in line to expand synthetic lethal drug class
As companies search for the successor to PARP, the ATR axis becomes a key contender
Items per page:
1 - 10 of 114